The drug, which is indicated for once-monthly use, will be available to patients in both a 70 mg and 140 mg self-administered auto-injector within 1 week of the approval.
Amgen, which will market Aimovig in partnership with Novartis, said the drug's price "reflects the value it brings to patients and society".
Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R) - which is believed to play a critical role in migraine. It will cost US$6,900 a year.More news: Uzbekistan assures USA on Afghanistan distribution route
The medicines are intended for the estimated 2.8 million Americans who have a migraine many times each month.
At the heart of this problem is an unresolved conflict between the business of pharmaceuticals driven by the discovery of new drugs through expensive research and the social and moral responsibility felt by emerging economies such as India to extend affordable medicine to all.
Erenumab is the first of 3 anti-CGRP drugs now under review to cross the FDA finish line. In a second study involving nearly 580 patients, participants using the drug experienced one fewer migraine day per month on average during a three month period. The companies expect approval in the European Union in the coming months. On average, the trial participants had 9.1 migraine days. These effects on monthly migraine days have been shown to be sustained for up to 15 months in an ongoing open-label extension study in episodic migraine (four to 14 headache days per month).More news: BSF trooper killed in Pakistan firing in Jammu
Lilly and Teva's drugs are jostling for second place, with Teva hoping for a verdict in the middle of 2018 for fremanezumab thanks to a priority review voucher that could carve six months off the review time. The drug is a pretty large step for those who suffer from migraines, as most pre-existing medications do not prevent all attacks, but can make them less severe and reduce their frequency.
Alder's eptinezumab is a slightly different proposition because it is given by infusion every three months for prevention - while the other three CGRPs are all given by subcutaneously - and its delivery route means it is also being tested as an acute migraine treatment.
Aimovig is just one of four different treatments now in development that target CGRP receptors. If approved, the drugs are expected to cost US$8,500 per year.More news: Elon Musk promises $1 tunnel rides at 240 kmph in LA
This article was originally published by Business Insider.